Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast
The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (US)
Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination r...
Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019
Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...